Arresto BioSciences

Management

Peter Van Vlasselaer, PhD
President and CEO, Arresto BioSciences

Peter joined Arresto BioSciences in March of 2007 as President and Chief Executive Officer. Before that, he was Chief Executive Officer of Avidia, Inc. Under his leadership, Avidia, Inc., brought a new class of biotherapeutic molecules into clinical development. Peter stayed with Avidia until it was acquired by AMGEN for $450 million at the end of 2006. Between 1999 and 2004, Peter was Senior Vice President of Technical Operations at InterMune, Inc. (ITMN), a company that develops products for the treatment of lung and liver diseases. Between 1993 and 1999, Peter was at Dendreon (DNDN) where he served as Vice President of Development. Dendreon develops cell based therapies for the treatment of cancer. Prior to that, Peter was a Staff Scientist at the Center for Nuclear Energy in Mol, Belgium where he conducted research in the areas of hematology and bone formation.

Peter obtained both a BS in Zoology and a PhD in Immunology magna cum laude from the Catholic University of Leuven, Belgium. He was a Post Doctoral Fellow at Stanford University and DNAX Research Institute (Schering Plough). Peter authored several peer reviewed publications and book chapters in the fields of immunology, hematology, bone formation and engineering and was inventor on more than 30 national and international patents.

Victoria Smith, PhD
Senior Director of Research and Development, Arresto BioSciences

Victoria Smith joined Arresto Biosciences in May 2007 to lead the Research and Development Department. She has more than 10 years of experience in the biotechnology industry and her experience covers discovery and oncology research. Most recently, Victoria held the position of Senior Scientis at Genentech (DNA). Her research has focused in the recent years on epithelial mesenchymal transfer biology and its relationship to the development and progression of cancer.

Victoria received a BSc with Honors from the University of Western Australia with majors in Physical and Inorganic Chemistry and Biochemistry and a Ph.D. from the University of Cambridge, United Kingdom, in Biology. She completed her postdoctoral studies at Stanford University, in the Departments of Genetics and Biochemistry. Victoria authored several peer reviewed scientific publications and she contributed to the filing of more than 1400 national and international patent filings covering novel gene discovery, oncology therapeutics, diagnostics, and novel methodologies.

Scott Ogg, PhD
Director Project and Alliance Management, Arresto BioSciences

Scott Ogg joined Arresto Biosciences in May 2007 to lead the Project and Alliance Management Department. He has more than 11 years of biomedical experience in research and early development of small- and large-molecule therapeutics. Most recently, Scott held the position of Associate Director Program Management at Nektar Therapeutics (NKTR). Previously, he was Associate Director of Research at Exelixis (EXEL).

Scott received a B.A. in Biology from Albion College and a Ph.D. in Cellular & Molecular Physiology from Tufts University Sackler School of Graduate Biomedical Sciences. He completed post-doctoral studies at Harvard University Medical School/Massachusetts General Hospital. He is author and inventor on several publications and patents.

Board of Directors

Beth Seidenberg
Chairperson
Partner, Kleiner Perkins Caufield and Byers

Beth joined Kleiner Perkins Caufield & Byers in May 2005 to work in the life sciences area.

For the past 20 years, she has focused her career on introducing new innovative treatments for AIDS, arthritis, asthma, cancer, psoriasis, cardiovascular, metabolic, neurological and renal disorders. She introduced 10 innovative products to market and achieved over 40 regulatory approvals (including new indications and formulations) on a worldwide basis.
Prior to joining KPCB, Beth was Senior Vice President, Global Development, and Chief Medical Officer at Amgen, Inc.,

Beth received her BS from Barnard College magna cum laude, Phi Beta Kappa; and her medical degree from the University Of Miami School Of Medicine, alpha omega alpha. Her post-graduate training was completed at Johns Hopkins, George Washington School of Medicine and the National Institutes of Health.

Joseph Lacob
Director
Partner, Kleiner Perkins Caufield and Byers

Joe Lacob has been a partner at Kleiner Perkins Caufield & Byers since 1987. He has been closely involved with KPCB's investments in over fifty life science companies, including the start-up or incubation of a dozen ventures and with KPCB's medical technology practice, which includes over thirty therapeutic and diagnostic medical device companies. Joe is also active in KPCB's new media and Internet company initiatives. He led the firm's investment in Sportsline.com, eHealthInsurance and AutoTrader.com.

Joe currently serves on the Board of Directors of two public companies, Align Technology and Orexigen, as well as several other privately-held companies including Ophthonix, NeuroPace, TherOx, BAS Medical and Codon Devices.

Joe is actively involved in industry organizations including the American Heart Association and the AHA Roundtable. He is also very involved at Stanford University, serving on advisory boards at the Medical Center, Business School and Athletic Department.

Joe received his Bachelor's in Biological Sciences from the University of California at Irvine, his Master's in Public Health from UCLA and his M.B.A. from the Stanford Graduate School of Business.

Augustine Lawlor
Director
General Partner, HealthCare Ventures LLC

Mr. Lawlor has 16 years operating experience in biotechnology industry in finance, business development, mergers and acquisitions and general management. Before joining HealthCare Ventures he was chief operating officer of LeukoSite, Inc. Before joining LeukoSite, Mr. Lawlor was chief financial officer and vice president of corporate development for Alpha-Beta Technology. He was previously chief financial officer and vice president of business development of BioSurface Technology.
Mr. Lawlor is a member of the board of directors of the Slater Center in Providence, Rhode Island. He received a master’s degree in management from Yale University.

Peter Van Vlasselaer
President and CEO, Arresto BioSciences

Founders

Amato Giaccia, PhD.
Jack, Lulu, and Sam Willson Professor of Cancer Biology, Director of Cancer Biology Graduate Program, Director Division of Cancer and Radiation Biology

Department of Radiation Oncology, Stanford University School of Medicine

After coming to Stanford in 1989 as a postdoctoral fellow, Professor Giaccia was promoted to Assistant Professor in 1992 and subsequently made the important discovery that the low oxygen microenvironment of solid tumors acted as a selective pressure for the expansion of tumor cell variants that were highly aggressive due to the loss of the p53 and PTEN tumor suppressor genes. These highly cited studies provide insight into the role of the tumor microenvironment on tumor evolution, and why solid tumors are resistant to chemotherapy and radiotherapy. In 2006, he was named the Jack, Lulu and Sam Willson Professor of Cancer Biology. Amato is currently the Director of the Interdisciplinary Cancer Biology Research Program at Stanford and is the Director of the Division of Radiation and Cancer Biology. He also heads the Radiation Biology Program in Stanford’s Cancer Center.

Amato has recently identified a critical gene, lysyl oxidase that is essential for the metastatic spread of tumor cells. This gene represents a new therapeutic target for the prevention and control of metastases. Amato is the principal investigator of an NIH Program Project Grant that is based on developing new strategies to exploit the tumor microenvironment. Amato has co-authored the sixth edition of the most prominent textbook in the field, “Radiation Biology for the Radiologist”, with Eric Hall from Columbia University. He also published close to 170 peer reviewed articles, book chapters and reviews and is inventor on 6 patents.

Amato was awarded an American Cancer Society Junior Faculty Research Award, Howard Hughes Junior faculty Award and the Michael Fry Award from the Radiation Research Society for his outstanding contributions on understanding the molecular mechanisms of resistance promoted by the tumor microenvironment.

Amato earned his undergraduate degree from Lafayette College and his Ph.D. from the University of Pennsylvania. He completed a postdoctoral fellowship with Dr. Martin Brown at Stanford University.

Michael T. Longaker, M.D., M.B.A., FACS
Deane P. and Louise Mitchell Professor, Director, Children’s Surgical Research, Deputy Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Director, Program in Regenerative Medicine,
Department of Surgery, Stanford University School of Medicine, Lucile Salter Packard Children’s Hospital

Dr. Michael T. Longaker has the responsibility to develop a children’s surgical research program in the broad areas of developmental biology, epithelial biology and tissue repair, tissue engineering and regenerative medicine.

Mike’s extensive research experience includes the cellular and molecular biology of extracellular matrix with specific applications to the differences between fetal and post-natal wound healing, the biology of keloids and hypertrophic scars and the cellular and molecular events that regulate craniofacial development and repair Most recently, his research has focused on multipotent mesenchymal cells derived from adipose tissue and their applications for tissue repair, replacement and regeneration. Mike has published over 850 scientific articles.

He is a member of the Society of University Surgeons, American Surgical Association and one of a limited number of surgeons elected into the Institute of Medicine of the National Academies of Science and American Society for Clinical Investigation. Currently, President of the Society of University Surgeons, and is the past President of the Plastic Surgery Research Council.

Mike earned his undergraduate degree at Michigan State University (with highest honors) and his medical degree at Harvard Medical School. He completed his surgical residency at the University of California, San Francisco, a residency in Plastic Surgery at NYU and a craniofacial fellowship at UCLA. The majority of his research training took place while he was a Post Doctoral Research Fellow in the Fetal Treatment Program under Dr. Michael Harrison and in the laboratory of Dr. Michael Banda in Radiobiology, both at UCSF. Mike also earned his M.B.A. from University of California – Berkeley and Columbia University, in the inaugural class of their combined program.

Geoffrey C. Gurtner, MD
Associate Professor of Surgery, Stanford University Medical Center, Executive Faculty Biodesign Program,

Dr. Geoffrey C. Gurtner is the Director of Breast and Aesthetic Surgery at the Stanford Cancer Center and an Associate Professor of Surgery at Stanford. Before that he was Formerly Program Director of Plastic Surgery, NYU Medical Center and Chief of Microsurgery, Bellevue Hospital.

Geoff’s clinical practice is focused on the treatment and reconstruction of women with cancer. His NIH funded laboratory is focused on the role of the physical environment (both mechanical and redox) in determining whether the biological response to injury is characterized by either fibrosis or tissue regeneration. Geoff’s research has led to the development of novel technologies which are currently being commercialized with the goal of optimizing tissue repair in humans. Geoff is the author of over 80 peer-reviewed publications and is the Editor of the most widely read textbook in the field, Grabb & Smith’s Plastic Surgery. He is also inventor on 15 Patents/Applications in Area of Vascular Biology, Tissue Engineering, Wound Healing.

Geoff is a magna cum laude graduate of Dartmouth College and an AOA graduate of the University of California-San Francisco School of Medicine. He completed a general surgery residency at the Massachusetts General Hospital/Harvard Medical School program, a plastic surgery residency at the NYU School of Medicine and received advanced training in cancer reconstruction at the University of Texas-MD Anderson Cancer Center.

Return To Top